Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 18 2022 - 7:00AM
Business Wire
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a late clinical stage biotechnology company
dedicated to developing life-changing medicines through science and
innovation for patients and families living with diseases, today
announced that N. Scott Fine, Chief Executive Officer of Cyclo
Therapeutics, will present at the H.C. Wainwright Global Investment
Conference being held May 23-26, 2022 in Miami, FL and
virtually.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference. For more information, please visit the conference
website.
A video webcast of the presentation will be available for
viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET
for those registered for the event and will be accessible on the
Events page in the Investors section of the Company’s website
(cyclotherapeutics.com). The webcast replay will be archived for 90
days following the event.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is being studied in a
Phase 3 pivotal clinical trial for Niemann-Pick Disease Type C, a
rare and fatal genetic disease, (www.ClinicalTrials.gov
NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company
is planning a Phase 2 clinical trial using Trappsol® Cyclo™
intravenously in Alzheimer’s Disease based on encouraging data from
an Expanded Access program for late-onset Alzheimer’s Disease
(NCT03624842). Additional indications for the active ingredient in
Trappsol® Cyclo™ are in development. For additional information,
visit the Company’s website: www.cyclotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005705/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From May 2023 to May 2024